Table 1

Survival and Tumor Growth Analysis

0.4% Direct Topical Rapamycin

0.8% Indirect Topical Rapamycin

0.8% Direct Topical Rapamycin

0.16 mg Injected (IP) Rapamycin

Direct Topical Vehicle


    Median Survival (days)

41

54

46

74.5

29.5

Logrank Analysis*

p = 0.0003

p =< 0.0001

p =< 0.0001

p =< 0.0001

N/A

Logrank Analysis**

p = 0.62

p = 0.0003

N/A

p =< 0.0001

N/A

    Ave. Tumor Vol. (mm3)

Day 29

1568 ± 155

1136 ± 101

1212 ± 118

440 ± 65

2736 ± 321

T test*

p = 0.0014

p =< 0.0001

p =< 0.0001

p =< 0.0001

N/A

T test**

p = 0.08

p = 0.63

N/A

p = 0.0001

N/A

Day 45

N/A

2235 ± 246

2869 ± 188

944 ± 166

N/A

T test**

N/A

p = 0.06

N/A

p =< 0.0001

N/A

    Number of Mice

15

12

13

8

12


*Compared to vehicle.

**Compared to 0.8% direct topical rapamycin

Rauktys et al. BMC Dermatology 2008 8:1   doi:10.1186/1471-5945-8-1

Open Data